Antiproliferative activity of liposome-encapsulated transforming growth factor-beta against MDA-MB-435 human breast carcinoma cells
Related Experiment Videos
1Department of Cell Biology, University of Texas M. D. Anderson Cancer Center, Houston 77030.
Abstract:
We determined whether transforming growth factor-beta (TGF-beta) could be encapsulated in phospholipid liposomes and then would mediate antiproliferative activity against the sensitive, human breast cancer cell line, MDA-MB-435. TGF-beta was encapsulated in multilamellar liposomes consisting of phosphatidylcholine (PC) or PC and phosphatidylserine (PS) at a 7:3 molar ratio. It was captured in both the aqueous phase and the bilayer lipid (hydrophilic and lipophilic association) and was stable for at least 24 hr of incubation at 37 degrees C in medium that contained 5% fetal bovine serum. In calcium- and magnesium-free Hanks' balanced salt solution, TGF-beta in the internal aqueous compartment was stable for at least five days, even in the presence of trypsin and ethylenediamine tetraacetic acid. TGF-beta (type 1 or 2) in liposomes was active as free-form TGF-beta in mediation of antiproliferative effects. The lipophilic nature of TGF-beta, which resulted in a high capture ratio in liposomes, coupled with exceptional stability, suggested that liposomes could be a carrier for the in vivo use of TGF-beta.
Insights
Transforming growth factor-beta (TGF-beta) can be effectively encapsulated in liposomes, maintaining its stability and antiproliferative activity against breast cancer cells. This suggests liposomes are a viable delivery system for TGF-beta in vivo cancer treatments.
Area of Science:
- Biotechnology
- Cancer Research
- Drug Delivery
Background:
- Transforming growth factor-beta (TGF-beta) is a crucial cytokine with antiproliferative properties.
- Effective delivery of TGF-beta for therapeutic applications remains a challenge.
Purpose of the Study:
- To determine if TGF-beta can be encapsulated in phospholipid liposomes.
- To assess the stability and antiproliferative activity of liposome-encapsulated TGF-beta against human breast cancer cells (MDA-MB-435).
Main Methods:
- Encapsulation of TGF-beta in multilamellar liposomes composed of phosphatidylcholine (PC) or PC/phosphatidylserine (PS).
- Assessment of TGF-beta stability in liposomes under various conditions (incubation in cell culture medium, Hanks' balanced salt solution).
- Evaluation of the antiproliferative activity of liposomal TGF-beta on MDA-MB-435 cells.
Main Results:
- TGF-beta was successfully captured in both the aqueous phase and lipid bilayer of liposomes.
- Liposomal TGF-beta demonstrated stability for at least 24 hours in cell culture medium and up to five days in a specialized salt solution.
- Encapsulated TGF-beta retained its ability to mediate antiproliferative effects on MDA-MB-435 breast cancer cells.
Conclusions:
- Liposomes can effectively encapsulate TGF-beta, preserving its biological activity.
- The lipophilic nature and stability of TGF-beta contribute to high capture ratios and sustained release from liposomes.
- Liposomes represent a promising carrier system for the in vivo administration of TGF-beta for cancer therapy.